FDA Recalls Two More Eyedrop Product Lines Because Of Safety Issues

Health officials in the United States are informing the public about two further recalls of eyedrops owing to contamination hazards that might cause vision impairment and severe harm.

The developments follow the recall of eyedrops manufactured in India last month, connected to an epidemic of drug-resistant diseases. At least five individuals suffered an irreversible visual loss.

There is no evidence that the most recent product recalls involve these products.

After the businesses voluntarily withdrew multiple product lots from the market, the Food and Drug Administration issued separate recall letters for certain eyedrops marketed by Pharmedica and Apotex. According to both companies, the recalls were undertaken in conjunction with the FDA.

Pharmedica announced on Friday that it is recalling two lots of Perfectly Soothing 15% MSM Drops due to “potentially blinding” issues. The eye drops sold over-the-counter are intended to alleviate eye discomfort. The company based in Phoenix advised consumers to immediately cease using the product and return it to the store where it was purchased.

According to the corporation, almost 2,900 bottles are affected by the recall. In Arizona, the drops were made.

The FDA published a separate recall notice from Apotex last week, recalling six lots of prescription eyedrops used to treat glaucoma. The company stated that it initiated the recall after discovering cracks in several bottle caps.

The eye drops are distributed as Brimonidine Tartrate Ophthalmic Solution 0.15 percent and sold from April through February last year.

According to an Apotex email, the eyedrops were made in Canada. There have been no reports of injuries associated with the drops.